As biomarkers, serum KL-6 and monocyte count were evaluated in this study. The serum KL-6 concentration was measured using a Nanopia KL-6 assay (SEKISUI MEDICAL, Tokyo) using a latex-enhanced immunoturbidimetric assay method. The monocyte count was calculated using white blood cell differential on CBC. Serum KL-6 ≥ 1000 U/mL is well known to predict poor prognosis in IPF, and, as such, was set as the cut-off value in this study15 (link),17 (link),26 (link). However, the optimal cut-off value of monocytes has not yet been validated. Therefore, we arbitrarily set monocytes ≥ 600/μL as a cut-off value based on recent studies20 (link),21 (link). Moreover, to determine whether the interval change in KL-6 level is related to DP, we divided patients into two groups according to the KL-6 level at the 3rd month from the baseline. Patients who had increased KL-6 levels at the 3rd month compared to baseline level were classified as the increased KL-6 group, and other patients were classified as the non-increased KL-6 group.
Free full text: Click here